Transforming Heart Failure Care: Restore Medical Partners Raises $23M in Series B Funding for ContraBand™ Innovation

Restore Medical Partners is proud to announce a major funding milestone with a successful raise of $23,000,000, marking a significant step forward in our mission to transform care for patients suffering from congestive heart failure (CHF). As one of the leading causes of death and hospitalization worldwide, CHF poses immense challenges for millions who continue to experience debilitating symptoms despite receiving state-of-the-art medical treatments. With this new capital infusion, we are set to accelerate the development and broader clinical adoption of our innovative solution, ContraBand™. This novel, catheter-delivered implant is designed to improve patients’ quality of life and reduce the high rates of hospital readmissions that have long burdened both patients and the healthcare system. The funds will not only drive further research and clinical trials aimed at validating ContraBand™'s safety and effectiveness, but they will also pave the way for enhanced manufacturing capabilities and strategic partnerships within the healthcare ecosystem. Our team remains steadfast in our commitment to revolutionizing care for CHF patients by addressing an unmet need in the current treatment paradigm. By supporting our efforts to bring a transformative solution to market, our investors have played a crucial role in helping us move closer to a future where CHF patients can enjoy improved health outcomes and a more vibrant life. This achievement underscores our dedication to fostering innovation, advancing cardiovascular care, and ultimately changing the landscape of heart failure management for millions worldwide.